Background: While a low estimated glomerular filtration rate (eGFR) confers an increased risk of dying, the mortality associated with high eGFR values has not been ascertained. Methods: Four variable MDRD-derived eGFR was calculated in a total of 33,386 patients (18,620 F, 14,766 M) aged ≧50 years (median 68 years, IQR 60–76 years) collected by family doctors in 2000. They were then classified according to their eGFR into 30 ml/min/1.73 m2 bands (<30, 30–59, 60–89, 90–119, 120–150). The subsequent mortality status of each patient was determined at 31st December 2006 and cause of death recorded where available. Results: Applying Cox proportional hazards models (adjusted for age and gender), the hazard ratio (HR) of dying compared to a reference of patients with eGFRs of 60–89 ml/min/1.73m2 was, as expected, higher in the low eGFR bands (HR 1.37 (95% CI 1.29–1.45) for 30–59; HR 2.60 (2.31–2.93) for <30 ml/min/1.73 m2, both p < 0.0001). However, it was also greater amongst patients with higher eGFRs (HR 1.29 (1.19–1.41) for 90–119; HR 2.63 (2.16–3.21) for 120–150 ml/min/1.73 m2, p < 0.0001). Circulatory disease was the main cause of death in patients with low eGFRs and respiratory disease/cancer, in patients with high eGFRs. Conclusions: As a marker of mortality, both low and high eGFRs are equally predictive of increased mortality in community patients, exhibiting a ‘U’ shaped curve. Thus, current CKD guidelines which recommend inaction or even the non-reporting of eGFR values greater than 60–90 ml/min/1.73 m2 may not identify patients who are at an equally high risk of dying as those where intervention is recommended.

Keywords:
Mortality, Estimated glomerular filtration rate
1.
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: A position statement from kidney disease. Improving global outcomes (KDIGO). Kidney Int 2005;67:2089–2100.
2.
National Service Framework for Renal Services – Part Two: Chronic kidney disease, acute renal failure and end of life care, 2005. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4101902. Accessed Jan 21, 2007.
3.
Royal College of Physicians: Chronic Kidney Disease in Adults, UK guidelines for identification, management and referral, 2006. Available at: http://www.renal.org/CKDguide/full/CKDprintedfullguide.pdf. Accessed Feb 24 2007.
4.
Lamb EJ, Tomson CRV, Roderick PJ: Estimating kidney function in adults using formulae. Ann Clin Biochem 2005;42:321–345.
5.
Levey AS, Greene T, Kusek JW, Beck GJ: MDRD study group, a simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A.
6.
Best PJM, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM: Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004;148:230–242.
7.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–147.
8.
Go AS, Chertow GM, Fan DJ, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
9.
Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the united states. J Am Soc Nephrol 2002;13:745–753.
10.
Levey AS, Stevens LA, Hostetter T: Automatic reporting of estimated glomerular filtration rate: just what the doctor ordered. Clin Chem 2006;52:2188.
11.
Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PHM, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C: Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005;16:3728–3735.
12.
Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP: Cystatin c and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237.
13.
Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049–2060.
14.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–470.
15.
MacKenzie F: UK NEQAS for eGFR: a personal view, 2006. Available at: http://www.ukneqas.org.uk/GFR%20Estimations.pdf. Accessed Jan 18 2007.
16.
Neighbourhood Statistics – Hull, 2001. Available at: http://neighbourhood.statistics.gov.uk/dissemination/LeadTableView.do;jsessionid=ac1f930bce6f9509e2c7a8b464cb61794613fade9e4.e38PbNqOa3qRe34Ka3uKbNiSch50n6jAmljGr5XDqQLvpAe?a=3&b=276821&c=Hull&d=13&e=15&g=389985&i=1001x1003x1004&m=0&enc=1&dsFamilyId=47&bhcp=1. Accessed Jan 18 2007.
18.
World Health Organization: International Classification of Diseases (ICD), 1994. Available at: http://www.who.int/classifications/icd/en/. Accessed Jun 7 2007.
19.
Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;82:515–526.
20.
Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307–1315.
21.
Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002;61:1486–1494.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.